SCHEMBL1339156

SCHEMBL1339156

COC(=O)c1ccc(NNC(C)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.59
▸ CA2 P00918 3/20 0.59
▸ CA12 O43570 1/20 0.59
▸ CA7 P43166 1/20 0.59
▸ CA9 Q16790 1/20 0.59
▸ CA14 Q9ULX7 1/20 0.59
▸ TSHR P16473 2/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ ALOX5 P09917 1/20 0.57
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ TDP1 Q9NUW8 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ LMNA P02545 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ MAPT P10636 4/20 0.51
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10383327 0.89 CA1 (0.55) CA1CA2CA12CA7CA9
SCHEMBL15541296 0.85 CA1 (0.59) CA1CA2CA12CA7CA9
SCHEMBL2384508 0.82 CA1 (0.61) CA1CA2CA12CA7CA9
SCHEMBL3143658 0.80 TSHR (0.67) CA1CA2CA12CA7CA9
SCHEMBL863168 0.80 MEN1 (0.69) MEN1KMT2ATDP1ALDH1A1LMNA
SCHEMBL425146 0.78 PTGS2 (0.62) CA1CA2TSHRCYP3A4ALOX5
SCHEMBL23600 0.78 CA1 (0.80) CA1CA2CA12CA7CA9
SCHEMBL28993944 0.78 CA1 (0.80) CA1CA2CA12CA7CA9
SCHEMBL72464 0.78 CA1 (0.61) CA1CA2CA12CA7CA9
SCHEMBL15600318 0.78 CA1 (0.50) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 — — US disclosed
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
CN-100537568-C 6-substituted pyridoindolone derivatives, their preparation and therapeutic use SANOFI AVENTIS (FR) 2009-09-09 — — CN disclosed
CN-101312970-A 6-heteroaryl pyridoindolone derivatives, their preparation and their therapeutic use SANOFI AVENTIS (FR) 2008-11-26 — — CN disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 — — US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 — — US disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
CN-1956986-A 6-Substituted pyridoindolone derivatives, their preparation and therapeutic use SANOFI AVENTIS (FR) 2007-05-02 — — CN disclosed
CN-1729190-A 3-phenyl-substituted pyridoindolones, their preparation and therapeutic use SANOFI AVENTIS (FR) 2006-02-01 — — CN disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP CA1 4885/4885CA2 4865/4885CA12 4883/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD CA1 4884/4885CA2 4879/4885CA12 4870/4885
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD CA1 4564/4885CA2 4085/4885CA12 4682/4885
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CA1 4803/4885CA2 4546/4885CA12 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback